Stockreport

TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment [Yahoo! Finance]

Alkermes plc - Ordinary Shares  (ALKS) 
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
PDF positive topline clinical trial data for its narcolepsy treatment, Alixorexton. Consequently, analysts at TD Cowen reiterated a Buy rating on the stock with a $40 price [Read more]